Dr. Rachna Ujwal is an associate in the patents and innovations practice in the Boston office of Wilson Sonsini Goodrich & Rosati. She focuses on strategic intellectual property counseling for clients in the life sciences industry ranging from venture-stage start-ups to growing biotherapeutic companies.
Rachna started with the firm in 2014 as a scientific advisor, rose to senior patent agent, and then transitioned to associate, after participating in the firm’s law school work-study program for patent agents to go to law school.
Prior to joining the firm, Rachna was a co-founder of a life sciences start-up providing research tools for characterizing membrane protein drug targets. She also gained experience at the UCLA Office of Intellectual Property, where she worked with the entrepreneurship and new ventures group.
Rachna's doctoral and postdoctoral research focused on understanding the structure-function relationship of membrane proteins involved in cardiovascular and metabolic pathways. She is the author of several scientific publications and has presented her research at numerous international conferences.
Rachna is admitted in New York. She is not yet admitted in Massachusetts and therefore not authorized to practice law in Massachusetts.
Dr. Rachna Ujwal is an associate in the patents and innovations practice in the Boston office of Wilson Sonsini Goodrich & Rosati. She focuses on strategic intellectual property counseling for clients in the life sciences industry ranging from venture-stage start-ups to growing biotherapeutic companies.
Rachna started with the firm in 2014 as a scientific advisor, rose to senior patent agent, and then transitioned to associate, after participating in the firm’s law school work-study program for patent agents to go to law school.
Prior to joining the firm, Rachna was a co-founder of a life sciences start-up providing research tools for characterizing membrane protein drug targets. She also gained experience at the UCLA Office of Intellectual Property, where she worked with the entrepreneurship and new ventures group.
Rachna's doctoral and postdoctoral research focused on understanding the structure-function relationship of membrane proteins involved in cardiovascular and metabolic pathways. She is the author of several scientific publications and has presented her research at numerous international conferences.
Rachna is admitted in New York. She is not yet admitted in Massachusetts and therefore not authorized to practice law in Massachusetts.
- J.D., Fordham University School of Law
- Ph.D., Molecular, Cellular, and Integrative Physiology, University of California, Los Angeles
- M.Sc., Biophysics, All India Institute of Medical Sciences, New Delhi
- B.Sc., Human Biology, All India Institute of Medical Sciences, New DelhiWith Honors
- State Bar of New York
- U.S. Patent and Trademark Office
- Not admitted in Massachusetts
- J.D., Fordham University School of Law
- Ph.D., Molecular, Cellular, and Integrative Physiology, University of California, Los Angeles
- M.Sc., Biophysics, All India Institute of Medical Sciences, New Delhi
- B.Sc., Human Biology, All India Institute of Medical Sciences, New DelhiWith Honors
- State Bar of New York
- U.S. Patent and Trademark Office
- Not admitted in Massachusetts
Select Publications
- "Affixing the N-terminal alpha helix of the voltage dependent anion channel to the channel's wall does not prevent its voltage gating," 287(14) Journal of Biological Chemistry 11437-45, 2012
- "High-throughput crystallization of membrane proteins using lipidic bicelle method," 59 Journal of Visualized Experiments e3383, 2012
- "Crystallizing membrane proteins using lipidic bicelles," 55(4) Method 337-41, 2011
- "Crystal packing analysis of mVDAC1 crystals in a lipidic environment reveals novel insights on oligomerization and orientation," 3(3) Channels 167-70, 2009
- "The crystal structure of mouse VDAC1 at 2.3A resolution reveals mechanistic insights into metabolite gating," 105(46) Proceedings of the National Academy of Sciences 17742-7, 2008
Select Publications
- "Affixing the N-terminal alpha helix of the voltage dependent anion channel to the channel's wall does not prevent its voltage gating," 287(14) Journal of Biological Chemistry 11437-45, 2012
- "High-throughput crystallization of membrane proteins using lipidic bicelle method," 59 Journal of Visualized Experiments e3383, 2012
- "Crystallizing membrane proteins using lipidic bicelles," 55(4) Method 337-41, 2011
- "Crystal packing analysis of mVDAC1 crystals in a lipidic environment reveals novel insights on oligomerization and orientation," 3(3) Channels 167-70, 2009
- "The crystal structure of mouse VDAC1 at 2.3A resolution reveals mechanistic insights into metabolite gating," 105(46) Proceedings of the National Academy of Sciences 17742-7, 2008
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
- Privacy Policy
- Terms of Use
- Accessibility